Antibody Drug Conjugates Market PDF | Growth | Trends | Forecast to 2021-2026

1. Global Antibody Drug Conjugates Market Research Report and Forecast 2021-2026 Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2019 IMARC All Rights Reserved

2. Report DescriptionAbout IMARC Group The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value challenges, and transform their businesses. opportunities, address their most critical IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Description and Highlights Report Description Global Antibody Drug Conjugates Market Outlook 2026: According to the latest report by IMARC Group, titled “Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global antibody drug conjugates market size reached US$ 4.3 Billion in 2020. Antibody drug conjugates (ADCs) refer to a class of biopharmaceutical drugs that are designed as a targeted therapy for treating cancer. They are made up of monoclonal antibodies (mAb) that chemically bind to specific receptors or proteins found on cancer cells. Upon entering the cells, the linked cytotoxic anticancer agents trigger the internalization of the antibody and allows sensitive bifurcation between healthy and diseased tissues. This, in turn, assists in enhancing the cell-killing potential of mAb, increasing drug tolerability, maximizing efficiency, and minimizing systematic exposure. Request for a free sample: https://www.imarcgroup.com/antibody-drug-conjugates- market/requestsample

4. Report Description and Highlights Report Description Global Antibody Drug Conjugates Market Trends: The global ADCs market is majorly being driven by the increasing prevalence of cancer due to sedentary lifestyle and rising number of smokers. In confluence with this, the shifting individual preference toward targeted and personalized cancer treatments is further facilitating the need for ADCs across the globe. Additionally, rising healthcare expenditures, along with rapid advancements in medical technologies to engineer novel linkers with additional antibody attachments to allow the expansion of payloads are acting as other growth-inducing factor. Furthermore, manufacturers are continuously investing in research and development (R&D) activities to optimize existing chemical triggers and improve the absorption, distribution, metabolism, and excretion, which are catalyzing the market growth. Other than this, vendors are increasingly collaborating with other companies to share resources, technology, product knowledge, and expand businesses. For instance, in 2019, Shanghai Miracogen entered into an agreement with Netherlands-based Synaffix to utilize its tools and resources for building ADCs. This, in turn, is creating a positive outlook for the market.

5. Report Description and Highlights Report Description Market Summary: Breakup by Component: • Monoclonal Antibodies • Linker • Cytotoxic Agent Breakup by Target: • Antibody-Protein Toxin Conjugates • Antibody-Chelated Radionuclide Conjugates • Antibody-Small-Molecule Drug Conjugates • Antibody-Enzyme Conjugates Breakup by Application: • Lymphoma • Ovarian Cancer • Lung Cancer • Breast Cancer • Brain Tumor

6. Report Description and Highlights Report Description Breakup by End User: • Hospitals • Specialized Cancer Centers • Academic Research Institutes • Biotechnology Companies Breakup by Region: • North America • Asia Pacific • Europe • Middle East and Africa • Latin America Looking forward, the market is expected reach a value of US$ 15.41 Billion to grow at a CAGR of around 23.70% during 2021-2026.

7. Report Description and Highlights Report Description Competitive Landscape With Key players: • ADC Therapeutics SA • Astellas Pharma Inc • AstraZeneca plc • Celldex Therapeutics Inc • F. Hoffmann-La Roche AG • Gilead Sciences Inc • GlaxoSmithKline Plc • ImmunoGen Inc • Pfizer Inc • Sanofi S.A • Seagen Inc • Sorrento Therapeutics Inc • Takeda Pharmaceutical Company Ltd View Report TOC, Figures and Tables: https://www.imarcgroup.com/antibody-drug-conjugates-market

8. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

9. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

10. Report Description and Highlights Report Description © 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

11. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com